0000882104-16-000143.txt : 20160603 0000882104-16-000143.hdr.sgml : 20160603 20160603161305 ACCESSION NUMBER: 0000882104-16-000143 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160603 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160603 DATE AS OF CHANGE: 20160603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 161695827 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdli-201606038xkdoc.htm 8-K Document


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 2, 2016

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 







Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 2, 2016, the Company held its 2016 Annual Meeting of Stockholders in Incline Village, Nevada. At the annual meeting, the Company’s stockholders: (i) elected each of Harold E. Selick, Ph.D., Paul R. Edick and Samuel R. Saks, M.D. to the Company’s Board of Directors for a term of three years, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016, and (iii) approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s 2016 proxy statement.
Represented in person or by proxy at the annual meeting were 142,989,966 shares of the Company’s common stock, or 86.6% of the total number of shares outstanding as of the record date. The results of the matters submitted to a stockholder vote at the annual meeting were as follows.
1.    Election of Directors:
Name
 
For
 
Withheld
 
Broker Non-Votes
Harold E. Selick, Ph.D.
 
104,551,441
 
4,751,258
 
33,687,267
Paul R. Edick
 
107,097,015
 
2,205,684
 
33,687,267
Samuel R. Saks, M.D.
 
106,927,147
 
2,375,552
 
33,687,267

2.
Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016:
For
Against
Abstain
 141,253,541
 1,222,892
513,533

3.
Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement:
For
 
Against
 
Abstain
 
Broker Non-Votes
103,938,223
 
4,541,790
 
822,686
 
33,687,267





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ Christopher Stone
 
 
Christopher Stone
 
 
Vice President, General Counsel and Secretary




Dated: June 3, 2016